Skip to content
AnalystLens

Exelixis Annual Report, Year Ended Dec 31, 2013

Filing Date
Filed February 20, 2014
Period End
December 31, 2013
Security
EXEL
In the record · 2016–202610-K1110-Q358-K119

EXEL filed 11 annual reports (10-K), 35 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’17Jan ’17
  2. Material agreement8-K · Apr ’19Apr ’19
  3. Leadership change8-K · Dec ’21Dec ’21
  4. Leadership change8-K · Nov ’25Nov ’25

Summary

Summary of the 10-K filed February 20, 2014. Cited figures are marked; the original filing is the authoritative source.

Exelixis, Inc. is a biotechnology company developing small molecule cancer therapies.

Its most advanced asset, COMETRIQ (cabozantinib), was approved by the FDA on November 29, 2012 for progressive, metastatic medullary thyroid cancer and became commercially available in late January 2013. In December 2013 the CHMP issued a positive opinion on the EU marketing authorization application, which the European Commission will review. The company reported a 2013 net loss of $244.8 milliona, an accumulated deficit of $1.5 billion, total revenues of $31.3 million (including $15.0 million of net product revenues from COMETRIQ), and cash and investments of $415.9 million at December 31, 2013.

It states it can fund operations for at least 12 months after the end of 2013, but its future capital requirements are substantial and it may need to raise additional capital earlier than expected. The company's debt load is significant: total consolidated indebtedness through maturity was $483.6 millionb, including $287.5 million of 4.25% convertible notes due 2019, $114.0 million of Deerfield secured convertible notes, and $82.1 million under a Silicon Valley Bank loan. In January 2014 Exelixis amended the Deerfield note purchase agreement to give it an option to extend those notes to July 2018 and issued 1,000,000 warrants at $9.70 per share.

It also sold 10.0 million shares at $8.00c per share in January 2014, raising about $75.6 million net. Management expects top-line data from several phase 3 pivotal trials of cabozantinib and cobimetinib in 2014, including COMET-1 and COMET-2 in prostate cancer, the overall survival analysis of the EXAM trial in MTC, and the cobimetinib/vemurafenib melanoma trial.

For investors, the key issues are the limited early commercial uptake of COMETRIQ, which the company says addresses an estimated 500 to 700 eligible U.S. patients per year, dependence on the outcome of 2014 pivotal trial readouts, and reliance on external financing and debt covenants. Revenue fell 34%d in 2013 as collaboration revenue from Bristol-Myers Squibb was fully recognized, and the company's history of losses is expected to continue.

Key Highlights

  1. FY2013 net loss of $244.8 million; accumulated deficit of $1.5 billion; revenues of $31.3 million, down 34% from 2012.
  2. COMETRIQ net product revenues of $15.0 million since its late January 2013 U.S. launch; wholesale acquisition cost of $10,395 per 28-day supply effective October 29, 2013.
  3. Cash and investments of $415.9 million at December 31, 2013, with management stating this supports operations for at least 12 months after year-end 2013.
  4. Total consolidated indebtedness of $483.6 million, including $287.5 million of 2019 convertible notes, $114.0 million of Deerfield notes, and $82.1 million under the Silicon Valley Bank loan.
  5. January 2014 subsequent events: $75.6 million net proceeds from a 10.0 million share offering at $8.00 per share, and a Deerfield note extension option to July 2018 with 1,000,000 warrants at $9.70.
  6. Six ongoing phase 3 pivotal trials, with top-line results from four expected in 2014, including COMET-1 and COMET-2 in CRPC and the EXAM overall survival analysis.
  7. CHMP positive opinion in December 2013 on the EU marketing authorization application for COMETRIQ in progressive, unresectable, locally advanced or metastatic MTC; European Commission review pending.

Financial Statements

FY2013 against FY2012

Line itemFY2013FY2012Change
Revenue$31.34M$47.45M−34.0%
Cost of Revenue$1.12M$0—
Gross Profit$30.22M$47.45M−36.3%
R&D Expenses$178.76M$128.88M+38.7%
SG&A Expenses$50.96M$31.84M+60.1%
Operating Expenses$232.07M$169.89M+36.6%
Operating Income-$200.73M-$122.44M−63.9%
Interest Expense$38.78M$24.78M+56.5%
Net Income-$238.19M-$145.34M−63.9%
EPS (Basic)$-1.29$-0.92−40.2%
EPS (Diluted)$-1.33$-0.92−44.6%
Shares Outstanding (Basic)184.06M160.14M+14.9%
Shares Outstanding (Diluted)184.06M160.14M+14.9%

Frequently Asked Questions

  1. How much revenue did Exelixis generate in 2013 and what drove the change?

    Total 2013 revenues were $31.3 million, compared with $47.5 million in 2012, a 34% decline. The filing attributes the decrease mainly to the full recognition of revenue from collaboration agreements with Bristol-Myers Squibb, partly offset by $15.0 million in net COMETRIQ product revenues.

  2. What is the company's cash position and how long can it fund operations?

    Cash and investments totaled $415.9 million at December 31, 2013. Management anticipates these resources, together with product revenues, will enable operations for at least 12 months following the end of 2013, but says future capital requirements will be substantial and additional capital may be needed sooner than expected.

  3. What debt obligations does Exelixis have that could affect investors?

    Total consolidated indebtedness through maturity was $483.6 million at year-end 2013. This includes $287.5 million of 4.25% convertible senior subordinated notes due August 2019, $114.0 million of Deerfield secured convertible notes with a mandatory 2015 prepayment of 15% of certain collaboration revenues (capped at $27.5 million), and $82.1 million under a Silicon Valley Bank loan and line of credit that carries covenants requiring deposit balances.

  4. What are the main near-term catalysts for the company?

    The company expects top-line data in 2014 from COMET-1 and COMET-2 (metastatic CRPC), the overall survival analysis of the EXAM trial for COMETRIQ in MTC, and the Roche/Genentech phase 3 trial of cobimetinib with vemurafenib in melanoma. It also expects the European Commission decision on the COMETRIQ marketing authorization application following the CHMP positive opinion.

  5. How large is the market for COMETRIQ and what is its pricing?

    The company estimates 500 to 700 first- and second-line metastatic MTC patients are diagnosed each year in the United States and eligible for COMETRIQ. The wholesale acquisition cost, effective October 29, 2013, is $10,395 for a 28-day supply, and the drug is flat priced across dosage strengths. Management states it expects only limited revenues from MTC alone.